Main Uses and Benefits of Статиглин (Glibenclamide)

Статиглин is generally used for the long-term management of Type 2 Diabetes Mellitus, providing supportive pharmacological assistance when initial efforts involving diet and exercise have proven insufficient to lower and stabilize glucose levels. It is commonly used for managing chronic elevated blood sugar levels (hyperglycemia) in adults. The medication supports metabolic stability when used alongside these lifestyle measures. The key therapeutic benefit is achieving sustained glycemic control, which generally contributes to the maintenance of functional stability for managing the condition.

The medication supports the management of immediate, distressing symptoms associated with uncontrolled blood sugar, such as constant excessive thirst and frequent urination (polyuria), which may help improve daily comfort. Its sustained benefit may assist with the long-term goal of mitigating the potential for progressive, serious diabetes-related complications, including damage to the nerves, eyes, and kidneys, supporting general well-being over time.

“The goal is to maintain a sense of stability when symptoms are more noticeable and support the overall symptom load.”

Quick Fact: Support for Metabolic Stress
Main Use	Supports glycemic control in Type 2 Diabetes Mellitus
Symptom Focus	Helps address excessive thirst and fatigue related to high sugar
Scenario	Applied when lifestyle management alone is insufficient
Benefit	Assists with mitigating the potential for long-term complications

Regulatory References

1. NIH MedlinePlus overview of Glyburide

The eligibility for using Статиглин (Glibenclamide) is strictly defined by regulatory documents, allowing its use only in specific patient populations.

Official Eligibility and Contraindications

Classification	Status & Eligible Population
Established Use	Adults with Type 2 Diabetes Mellitus whose glucose control is inadequate with diet and exercise alone.
Absolute Contraindications	Type 1 Diabetes Mellitus or Diabetic Ketoacidosis. Patients with known hypersensitivity to the drug or other sulfonamides. Use is forbidden with concomitant Bosentan therapy.

---

Population-Specific Limitations

Organ Function: The medicine is contraindicated in patients with severe hepatic or severe renal impairment due to the increased risk of prolonged hypoglycemia. Use in patients with mild-to-moderate dysfunction requires caution.

Age & Reproductive Status: Use in the pediatric population is not established and not recommended. The medicine is contraindicated in pregnancy and not recommended during breastfeeding. For older adults, the official labeling advises caution and conservative starting due to susceptibility to hypoglycemia.

Interactions with other medicines and products

Статиглин is a combined medication containing sitagliptin (a dipeptidyl peptidase-4 (DPP-4) inhibitor) and a statin (an HMG-CoA reductase inhibitor). Therefore, its potential drug interactions stem from both active components.

Sitagliptin Interactions

The primary concern when sitagliptin is combined with other antidiabetic medicines is an increased risk of hypoglycemia (low blood sugar). This applies particularly to agents like sulfonylureas (e.g., glipizide, glimepiride) and insulin. Dosage adjustments of these concomitant medications may be necessary. Certain strong inhibitors of the CYP3A4 enzyme, such as the antifungal drugs ketoconazole and itraconazole, or the HIV medication ritonavir, may modestly increase sitagliptin concentration, though this is not usually considered clinically significant enough to warrant routine dose adjustment.

Statin Interactions

The statin component is susceptible to numerous interactions, mainly through the cytochrome P450 (CYP) enzyme system (specifically CYP3A4 for many statins). Co-administration with the following can significantly increase statin blood levels, raising the risk of serious muscle side effects, including rhabdomyolysis:

• Potent CYP3A4 Inhibitors: Certain antifungals (itraconazole, ketoconazole), some macrolide antibiotics (clarithromycin), and HIV protease inhibitors.
• Fibrates (e.g., gemfibrozil): Concurrent use increases the risk of muscle toxicity. Combining the statin with certain fibrates is often avoided or requires strict dose limitation and monitoring.
• Cyclosporine (an immunosuppressant) also increases statin exposure, often requiring the lowest possible statin dose or avoidance.

Patients should inform their healthcare provider of all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements they are taking to properly manage potential interactions.

Статиглин (Saxagliptin) is a small molecule inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). The molecule forms a reversible, histidine-assisted covalent bond with the S630 hydroxyl oxygen on the DPP-4 enzyme, resulting in competitive inhibition of its enzymatic activity.

The inactivation of DPP-4 prevents the rapid degradation of incretin hormones, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), leading to increased and sustained systemic concentrations of their active forms. Elevated GLP-1 and GIP primarily target pancreatic beta cells and alpha cells.

Within the pancreatic beta cells, increased active incretins signal for enhanced glucose-dependent insulin secretion. Concurrently, in the pancreatic alpha cells, the elevated GLP-1 concentration mediates the inhibition of glucagon production and release. The net systemic physiological consequence is the modulation of endogenous glucose homeostasis, resulting from augmented insulin signaling and attenuated glucagon counter-regulation, both in a glucose-responsive manner.

How to use Статиглин (Glibenclamide) — Official Administration Guidelines

Статиглин, containing Glibenclamide (Glyburide), is an oral medication. The official instructions for its administration define the specific route, timing, and dosing boundaries established for therapy. It is generally used as a long-term therapy for Type 2 diabetes management.

---

Administration Scope

Instruction	Detail
Route of administration	Oral (via tablet).
Timing in relation to meals	Must be administered with breakfast or the first main meal of the day.
Missed-dose rules	If a dose is missed, patients should skip the missed dose if it is almost time for the next dose; the dose should not be doubled.

---

Labeled Dosing and Scheduling Principles

Therapy is initiated at a low level, with the initial dose for the standard tablet typically ranging from 2.5 mg to 5 mg once daily. The standard tablet has an established maximum daily dose of 20 mg. Dose adjustments are meant to be gradual, occurring at weekly intervals and not exceeding 2.5 mg increments for the standard formulation.

For higher maintenance dosing (e.g., above 10 mg for the standard tablet), the total amount should be taken in divided doses (typically twice daily). Official guidelines mandate a conservative initial dose for specific patient populations, including older adults (geriatric patients) and those with hepatic or renal impairment, often starting at 1.25 mg once daily. Furthermore, because standard and micronized tablet forms are not bioequivalent, official protocols require the initiation of a new dose titration upon switching between formulations.

Research evidence / Overview of studies for Статиглин

Research has primarily explored this medication in adults diagnosed with Type 2 Diabetes Mellitus (T2DM). Studies, including Randomized Controlled Trials (RCTs), tracked outcomes related to systemic or functional imbalance, such as levels of Glycated Hemoglobin ( HbA1c) and daily blood glucose. Findings described patterns related to measured changes in average blood glucose in the study population. Research also examined biomarkers related to metabolic function and long-term endpoints like cardiovascular events, though comparative evidence on macrovascular outcomes is lacking or complex in some studies.

The medication was evaluated in studies involving pregnant women diagnosed with Gestational Diabetes Mellitus (GDM). These studies monitored outcomes related to maternal blood glucose control and key fetal outcomes like birth weight. Studies reported measurements related to maternal blood glucose levels, but trials also reported measurements related to macrosomia, and findings were mixed across various studies. The specific reasons behind the patterns reported for fetal outcomes remains an area of ongoing study.

Concerning Long-Term Studies and Durability of Effect, there is limited information for long-term outcomes that go beyond the initial observation periods. Research is ongoing to provide context on the durability of the effect. For Special Populations, research has focused on the T2DM and GDM groups, but comparative evidence is lacking for many other special populations, such as children. There are several areas where certainty remains low, including the full picture of macrovascular complications and the long-term metabolic effects on newborns, where the evidence is limited for these extended outcomes. This research provides context but not individual predictions, and evidence highlights what is known — and what is still uncertain.

Key Studies & References

1. Effects of different hypoglycaemic drugs on beta-cell function in type 2 diabetes mellitus: a systematic review and network meta-analysis
2. Glibenclamide - Electronic Essential Medicines List (eEML)
3. Glyburide: MedlinePlus Drug Information (for general context on sulfonylurea class mechanism and T2DM/GDM use)

Common questions about Статиглин (FAQ)

---

Q: Can I take this medication if I drink alcohol?

Regulatory information for the sitagliptin component of Статиглин does not list a specific interaction with alcohol. However, official product information for the statin component includes warnings about the risk of liver-related side effects. This risk can be increased by substantial alcohol use. Information about individual alcohol consumption should be discussed with a healthcare provider.

---

Q: What is the onset of action? When will I start to see results on my blood sugar and cholesterol?

Studies indicate that the sitagliptin component, which helps manage blood sugar, typically shows effects on long-term markers like HbA1c within weeks to a few months. The statin component begins working quickly to lower cholesterol production, with effects on lipid levels often noted within a few weeks of starting treatment. Achieving the full intended effect on these levels may take an extended period.

---

Q: Are there any food restrictions or necessary dietary changes while on this medication?

The sitagliptin component of the medicine is officially indicated for use as an addition to a controlled diet and exercise regimen. Additionally, regulatory documents for the statin component carry a specific warning about consuming grapefruit juice, as it can increase the amount of the drug in the bloodstream. Official product information contains a warning against the consumption of grapefruit juice while using this medication.

---

Q: What are the common side effects I should look out for?

Side effects frequently reported in official documents include upper respiratory tract infection, headache, and nasopharyngitis. When Статиглин is used with certain other diabetes medications, a risk of low blood sugar (hypoglycemia) exists. Official product information also warns about rare but serious concerns, such as inflammation of the pancreas (pancreatitis) and severe muscle problems.

---

Q: Is this medication safe to use during pregnancy or while breastfeeding?

Official regulatory documents generally advise against using Статиглин during pregnancy. The statin component, specifically, is contraindicated (prohibited) for use during pregnancy, and its use is also generally not recommended while breastfeeding. Regulatory documents indicate that women who may become pregnant are generally expected to use effective contraception while taking the statin component.

---

Q: Can children under 18 years old take this drug?

The fixed-dose combination product is generally not approved for use in pediatric patients (children and adolescents). While the sitagliptin component has been studied in adolescents (ages 10 to 17), regulatory documents indicate it has not been definitively proven to improve blood sugar control in this group and is not approved for children under 10 years of age.

---

Q: How long will I need to take this drug? Can I stop taking it once my levels are under control?

This medication is indicated for the chronic management of long-term conditions like high cholesterol and Type 2 diabetes. The decision to discontinue treatment is a medical one that must be made in consultation with a healthcare professional. Official guidelines describe that the drug is to be discontinued immediately if serious reactions are suspected, such as pancreatitis or muscle breakdown (rhabdomyolysis).

How to Store and Dispose of Статиглин (Glibenclamide)

Official regulatory documents define strict conditions for storing and disposing of Glibenclamide tablets to maintain stability and ensure safety.

---

Storage Requirements

Glibenclamide must be stored at room temperature, typically defined as not exceeding 25°C to 30°C. It is mandatory to keep the medication away from excess heat, direct light, and moisture, and it must be kept from freezing.

• The tablets must remain in the original container and be kept tightly closed.
• For safety, the medicine must be stored strictly out of the sight and reach of children.

---

Disposal Instructions

Unused or expired product must be disposed of in accordance with local requirements. The official guidance advises against releasing the product into the environment, including preventing it from entering drains or wastewater. Patients should consult a healthcare professional or pharmacist for specific local disposal instructions.